Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

111.26 113.10 73.61 60.38
P/S ratio
7.11 7.54 6.75 9.07
P/FCF ratio
38.60 41.09 30.30 41.86
P/Operating CF
313.52 111.21 94.27 115.48
P/B ratio
4.40 4.56 3.92 5.23
EV/Sales
7.25 7.62 6.75 9.03
EV/EBITDA
40.81 41.98 32.16 31.40
EV/FCF
39.35 41.54 30.31 41.66
Current Ratio
4.22 4.54 4.49 4.55
Net Debt/EBITDA
2.15 1.10 (0.10) (0.66)
Debt/Equity
0.15 0.13 0.10 0.09
Earnings Yield
0.90% 0.88% 1.36% 1.66%
Free Cash Flow Yield
2.59% 2.43% 3.30% 2.39%
Free Cash Flow per Share
0.14 0.49 0.50 0.56
Book value per Share
12.64 12.90 13.34 13.52
Free Cash Flow
22.22 76.49 77.58 86.94
EV/EBIT
80.20 79.21 53.15 43.54
Other line items

Show all line items

Columns are period end dates